Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Ian Hardcastle

Newcastle AuthorsTitleYearFull text
Dr Ian Hardcastle
Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Interaction2021
Christopher Matheson
Christopher Coxon
Dr Benoit Carbain
Dr Ian Hardcastle
Dr Suzannah Harnor
et al.		2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase2020
Daniel Wood
Daniel Lopez Fernandez
Leanne Knight
Islam Al-Khawaldeh
Dr Conghao Gai
et al.		FragLites - minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation2019
Stephanie Myers
Duncan Miller
Dr Lauren Molyneux
Dr Mercedeh Arasta
Dr Ruth Bawn
et al.		Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD42019
Dr Simon Hill
Dr Michael Dunn
Dr Celine Cano
Dr Suzannah Harnor
Dr Ian Hardcastle
et al.		Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification2018
Duncan Miller
Dr Mathew Martin
Santosh Adhikari
Alfie Brennan
Professor Jane Endicott
et al.		Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach2018
Amy Heptinstall
Dr Celine Cano
Dr Ian Hardcastle
Recent advances in CDK inhibitors for cancer therapy2018
Christopher Coxon
Dr Suzannah Harnor
Dr Mathew Martin
Dr Benoit Carbain
Professor Bernard Golding
et al.		Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines2017
Professor David Rees
Professor Bernard Golding
Dr Ian Hardcastle
Dr Celine Cano
Duncan Miller
et al.		ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY2017
Professor David Rees
Professor Bernard Golding
Dr Ian Hardcastle
Dr Celine Cano
Duncan Miller
et al.		Preparation of isoindolinones as inhibitors of the MDM2-​p53 interaction having anticancer activity2017
1234567891011